The following is a summary of “DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled trial,” published in the November 2023 issue of Dermatology by Eichenfield, et al.
Achieving patient adherence to antiacne medications is frequently a challenging task for healthcare providers. DMT310, a topical product derived from natural sources requiring a once-weekly application, can mitigate the issue. For a study, researchers sought to assess the safety, tolerability, and effectiveness of DMT310 in treating moderate-to-severe acne.
In a 12-week multicenter clinical trial, a randomized, double-blind, placebo-controlled design was implemented. Participants aged 12 and above, with moderate-to-severe acne were enrolled.
The intent-to-treat population consisted of 181 participants (91 in the DMT310 group and 90 in the placebo group). The individuals receiving DMT310 exhibited a statistically significant reduction in both inflammatory and noninflammatory lesion counts at all assessment time points compared to their counterparts in the placebo group. Notably, at week 12, inflammatory lesion counts decreased by −15.64 in the DMT310 group compared to −10.84 in the placebo group (P < .001), while noninflammatory lesion counts decreased by −18.26 for DMT310 and −12.41 for placebo (P < .001). Furthermore, the DMT310-treated participants achieved higher rates of success as assessed by the Investigator’s Global Assessment compared to the placebo group at all time points. At week 12, this difference was statistically significant (44.40% for DMT310 vs. 17.78% for placebo, P < .001). Notably, no serious treatment-related adverse events were reported.
DMT310, when applied topically once a week, resulted in a significant reduction in both inflammatory and noninflammatory lesions and an increased proportion of success based on the Investigator’s Global Assessment at all evaluation time points in participants with moderate-to-severe acne. The treatment approach showed promise in effectively managing this skin condition.